Citation & Authors
Diabetes Obes Metab. 2026;28(8):6973-6984.
ABSTRACT · RESEARCH SUMMARY
Research summary
This target trial emulation matched 78,940 patients per group, all aged ≥60 years with obesity but without diabetes. Compared with other weight-loss medications, GLP-1 drugs were associated with a lower risk of incident AMD (HR 0.82; 95% CI 0.68–0.98). Median follow-up differed between groups, and subgroup findings were exploratory. Direct drug effects cannot yet be distinguished from the influence of the amount of weight lost.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
